| Document |
Document Title |
|
WO/2024/081363A1 |
The disclosure features methods for treating cancer (e.g., immune refractory cancer) using a RAS inhibitor. The disclosure also features combination therapies containing one or more RAS inhibitors for treating cancer.
|
|
WO/2024/079009A1 |
The present invention relates to the combination therapy of anti-GPRC5D/anti-CD3 bispecific antibodies with proteasome inhibitors. The combination therapy may further comprise a glucocorticosteroid.
|
|
WO/2024/081372A1 |
The present invention relates to processes for the preparation of the compound of formula 1 from the intermediates the intermediates of formulae 8 to 10 in the presence of the cyclisation catalyst CuSO4 Compound 1 is the agent-linker con...
|
|
WO/2024/035884A8 |
Disclosed herein are kits and methods for treating pulmonary arterial hypertension (PAH), comprising administering to a subject in need thereof: • a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically ...
|
|
WO/2024/081404A1 |
The present disclosure is related to dietary supplements including compositions that include, one or more agents that increase γ-aminobutyric acid (GABA) binding with GABA-A receptor, increase serotonin concentrations, decrease dopamine...
|
|
WO/2024/080726A1 |
The present invention relates to a pharmaceutical composition containing natural killer cells and a topoisomerase inhibitor as active ingredients. The pharmaceutical composition according to the present invention exhibits cytotoxicity in...
|
|
WO/2023/183875A9 |
The disclosure features methods and compositions for the treatment of perivascular fibrosis and other hypertensive diseases and conditions, cardiovascular diseases, and chronic kidney disease.
|
|
WO/2024/077506A1 |
Atovaquone is used for treating and preventing acute and chronic inflammatory diseases in mammals, including mast cell-mediated inflammatory diseases.
|
|
WO/2024/081310A1 |
Described herein are engineered mammalian cells comprising a reduction in the level or function of one or more of a major histocompatibility complex (MHC) class I protein complex component, optionally, a MHC class II protein complex comp...
|
|
WO/2024/078568A1 |
Provided in the present invention are a treatment method for treating cancer patients accompanied by pain by using a combination of an AKR1C3 activated anticancer prodrug compound and an analgesic drug, a pharmaceutical use, a drug combi...
|
|
WO/2024/050426A3 |
The present invention provides methods and compositions for treating cancers, as well as methods for increasing an immune response against a tumor, in a subject in need thereof by decreasing the expression and/or activity of Stub1 in an ...
|
|
WO/2024/079364A1 |
The present invention relates to cladribine or a pharmaceutically acceptable salt, hydrate, solvate thereof for use in preventing and/or treating a bacterial infection, wherein said bacterial infection is caused by a gram negative bacter...
|
|
WO/2024/059525A3 |
Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for anaplastic lymphoma kinase (ALK) an...
|
|
WO/2024/079603A1 |
The present invention relates to novel pharmaceutical formulations given by the association of an inhibitor of histone methyltransferase activity and chemotherapeutic drugs for use in the treatment of cancer, in particular of colon cance...
|
|
WO/2024/081932A1 |
Provided are methods for the treatment of spinal muscular atrophy (SMA) in a fetal subject in need thereof comprising administering an amount of risdiplam to a carrier of the fetal subject. Administering the amount of risdiplam to the ca...
|
|
WO/2024/081674A1 |
Provided are methods of treating cancer (e.g, a cancer that comprises one or more cancer cells that express a KRAS G12C mutant protein and/or have at least one mTOR- activating aberration) in an individual that comprise administering a c...
|
|
WO/2024/081916A1 |
The present disclosure relates to methods of treating or preventing cancer using a compound of Formula (0): or a pharmaceutically acceptable salt thereof. The present disclosure also relates to pharmaceutical compositions and pharmaceuti...
|
|
WO/2024/077856A1 |
Provided in the present invention is the use of a TBX family transcription factor as a target in the preparation of a drug for treating ophthalmic diseases. In the present invention, the TBX family transcription factor is used as a targe...
|
|
WO/2024/054558A3 |
The present disclosure provides compositions and methods for the treatment of CLEC16A-associated phenotypes and disorders. The present disclosure further provides a method for treatment of CLEC-16A-associated degeneration of the thymus, ...
|
|
WO/2024/081309A1 |
Described herein are engineered mammalian cells comprising a reduction in the level or function of a major histocompatibility complex (MHC) class I protein complex component, and, optionally, a MHC class II protein complex component and/...
|
|
WO/2024/081969A1 |
Described herein are compounds, formulations, and methods for blocking sporozoite invasion and subsequent liver-stage parasite development of a protozoan parasite, such as Plasmodium falciparum. Also described herein are compounds, formu...
|
|
WO/2024/077099A1 |
Provided herein are methods of treating a cancer (e.g., a solid tumor) in a subject in need thereof. The present disclosure also provides methods of activating the immune system of a subject in need thereof (e.g., a subject having a canc...
|
|
WO/2024/074850A1 |
The present invention is directed to the treatment of mental disorders. For example, there is provided a combination of a rapid-acting indolealkylamine and a mood preparation agent for use in a method for treating a mental disorder the m...
|
|
WO/2024/074554A1 |
The present invention relates to compositions and methods for treating or preventing infections, in particular infections by intracellular parasites such as Cryptosporidium spp. The present invention also relates to compositions and meth...
|
|
WO/2024/077121A1 |
Oral care compositions that contain a particular mixture of mono-rhamnolipids and dirhamnolipids are disclosed. The compositions have antimicrobial efficacy against oral microbes, such as P. gingivalis, S. mutans, and C. rectus. Also dis...
|
|
WO/2024/074049A1 |
Provided are a pharmaceutical composition for thyroid undifferentiated cancer and use thereof in the preparation of a medicament for preventing and/or treating thyroid undifferentiated cancer. The pharmaceutical composition comprises jac...
|
|
WO/2024/074498A1 |
The present invention relates a therapeutic combination of a BTN3A activating antibody, a Bcl-2 family inhibitor and hypomethylating agents that is particularly useful for the treatment of cancer, in particular hematological malignancies...
|
|
WO/2024/075844A1 |
The present disclosure provides a technique for examining the acquisition risk of an inflammatory skin disease, the severity or the degree of progression thereof. The present disclosure provides a method for analyzing a biological sample...
|
|
WO/2024/076537A1 |
The present disclosure generally relates to technologies for treating cancer, including brain cancers such as a glioblastoma, methods of increasing the concentration of anthracy clines and immune checkpoint modulators in the brain of a s...
|
|
WO/2024/074959A1 |
This invention relates to talazoparib, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, for the treatment of metastatic castration-resistant prostate cancer a...
|
|
WO/2024/075803A1 |
The present invention addresses the problem of providing: a method for testing a cranial nerve disease including schizophrenia, or a method for testing the sensitivity to a cranial nerve disease; and a reagent and a kit for use in the te...
|
|
WO/2024/075696A1 |
The present invention addresses the problem of providing a novel compound having an SMG1 inhibitory activity and an anticancer effect, or a pharmaceutically acceptable salt thereof etc. A compound represented by formula (1) or a pharma...
|
|
WO/2024/071464A1 |
The present invention relates to anticancer uses of a maleate metal salt. Particularly, the present invention relates to a pharmaceutical composition for preventing or treating cancer and an anticancer adjuvant pharmaceutical composition...
|
|
WO/2024/073451A1 |
Provided herein are compositions, such as suitable for subcutaneous administration, and methods for treating ascites in an individual using a mixed V1A receptor agonist-antagonist.
|
|
WO/2024/067891A2 |
Disclosed in the present application are the use of an Aldo-Keto reductase family 1 member C3 (AKR1C3) inhibitor in the inhibition of lipid droplet generation and the promotion of lipid droplet degradation and in the preparation of a dru...
|
|
WO/2024/073356A1 |
The disclosure relates to 2-[2-ethoxy-4-(ethylsulfanyl)-5-methoxyphenyl]ethan-1-aminiu
m chloride (2-(2-ethoxy-4-(ethylthio)-5-methoxyphenyl)ethan-1-a minium chloride), crystalline 2-(2-ethoxy-4-(ethylthio)-5-methoxyphenyl)ethan-1-aminiu...
|
|
WO/2024/073473A1 |
Provided herein are methods of treating non-hemorrhagic closed head injury (NHCHI) with 3,3'-diindolylmethane or an analog thereof. In one embodiment, NHCHI covers Traumatic Brain Injuries (TBIs) including mild to severe concussion, blas...
|
|
WO/2024/073672A1 |
The present disclosure relates to methods of treating a kidney disease or disorder, including methods comprising administering sparsentan and a SGLT2 inhibitor to a subject in need thereof.
|
|
WO/2024/069589A1 |
Hexahydrocannabinol (HHC), hexahydrocannabidiol (H4CBD), and hexahydrocannabidivarin (H4CBDV) derivatives are disclosed. Also disclosed are pharmaceutical compositions comprising such derivatives. Further described are methods of use the...
|
|
WO/2024/073600A1 |
According to various aspects of this disclosure, the present disclosure relates to combination therapies, methods, and kits comprising MARCO blocking agents and anti-cancer agents for improvement of nanoformulated drug delivery. Further,...
|
|
WO/2024/069050A1 |
The invention relates to co-administration a CYP2D6 inhibitor with tasipimidine, or a pharmaceutically acceptable salt thereof, in order to improve the pharmacokinetic profile of tasipimidine by decreasing its clearance and inter-individ...
|
|
WO/2024/071401A1 |
The present inventors found that enhancement of Plk1 activity induces lethal chromosome dynamic abnormalities in cancer cells and inhibits the proliferation thereof. Thus, activation of Plk1 and exacerbation of chromosome instability can...
|
|
WO/2024/073334A1 |
Provided herein are methods of combined treatments using bupropion and/or its metabolites and zonisamide or other similar anticonvulsants or GABAergic agents, optionally in further combination with one or more nicotine replacement or sub...
|
|
WO/2024/071935A1 |
The present invention relates to: a pharmaceutical composition for treating cancer, the composition containing at least one from the group consisting of a histone deacetylase (hereinafter, referred to as HDAC) 6 inhibitor and a HDAC8 inh...
|
|
WO/2024/073328A2 |
The present invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject Compound 1 (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising Com...
|
|
WO/2024/073588A1 |
The present disclosure provides pharmaceutical compositions for use in delivering therapeutics, such as vaccines or biologic material, to the nasal cavity or the deep lungs. In particular, the pharmaceutical compositions may preferential...
|
|
WO/2024/071362A1 |
The present invention addresses the problem of providing a new method for improving the delivery efficiency of a drug such as a nucleic acid drug to the nervous system. Provided is a delivery enhancer for enhancing the delivery of a dr...
|
|
WO/2024/069344A1 |
The present invention relates to methods of treating or preventing cancer. In particular, the invention is directed to the use of selective non-peptide antagonists of the NK1 receptor (NK1R) in the treatment or prevention of cancer.
|
|
WO/2024/073648A1 |
Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of cancer as a monotherapy or a combination therapy with chemotherapeutic agents and/or checkpoint inhibitors.
|
|
WO/2024/073529A1 |
This disclosure relates to leukocyte compositions that comprise immune cells that are modified for enhanced in vivo anti-tumor activity. The leukocyte compositions are enriched for CD4+ Th1 cells or other differentiated states and option...
|
